

Potency of tamoxifen against clinical isolates of *Candida* resistant to itraconazole

Ali Abdul Hussein S. AL-JANABI* 

Department of Microbiology, College of Medicine, University of Karbala, Karbala, Iraq.

* Corresponding Author. E-mail: aljanabibio@gmail.com (A.A.A); Tel. +964-781-141 1260.

Received: 7 Jan 2023 / Revised: 5 Feb 2023 / Accepted: 9 Feb 2023

ABSTRACT: Tamoxifen (TAM) has been shown to have an antifungal action along with its anticancer activity. Various species of fungi have shown varying susceptibility to TAM. The antifungal activity of TAM was studied against clinical pathogenic species of *Candida* that are resistant to itraconazole through using disk diffusion and dilution methods. Of 50 isolates of *Candida* from women with vulvovaginal candidiasis, 15 isolates were resistant to itraconazole. These isolates consisted of four isolates of *C. albicans*, ten isolates of *C. glabrata* and one isolate of *C. utilis*. All isolates were inhibited by a high concentration of TAM (20 mg/ml). *Candida albicans* was affected by TAM at 10 mg/ml (MIC, 5.5-7 mg/ml). High susceptibility with a low MIC value of TAM (3 mg/ml) was observed in *Candida glabrata* isolates. *Candida utilis* was also found to be the isolate with the highest resistance to TAM (MIC, 15 mg/ml). In conclusion; TAM is an effective agent against drug-resistant species of *Candida* in high concentrations. It was also demonstrated that resistant isolates of *C. glabrata* are the most susceptible to TAM. High-dose of TAM is recommended for the treatment of fungal infections caused by drug-resistant species of *Candida*. Further studies are needed in this concern.

KEYWORDS: Keyword-1; keyword-2; keyword-3; keyword-4; keyword-5. Use semicolons (;) as separator.

1. INTRODUCTION

The treatment of fungal infections has always been faced with many challenges that may relate to the similarity between fungi and humans, as both are eukaryotic, or relate to the characters of the antifungal agents such as their limited number, cellular toxicity, low spectrum of activity and resistance development [1]. Many alternative compounds have been identified as effective antifungal agents. Tamoxifen (TAM), which is mainly used as an estrogen receptor antagonist for the treatment of breast cancer, is showing promising results as an antifungal agent [1-2]. Its antifungal activities have been demonstrated against a wide range of types of fungi. Yeasts are the fungi most commonly affected by TAM [3-5]. *Saccharomyces cerevisiae* was the first yeast shown to be affected by TAM where it inhibited after 60 minutes of treatment with 15 and 30 µg/ml of TAM [3]. Growth of *Schizosaccharomyces pombe* was also affected by TAM in which its colonies were completely absent under the effect of 40 µg/ml of TAM [6]. Recently, TAM has been shown to have an antifungal effect against many pathogenic types of yeast such as *Candida* spp. and *Cryptococcus neoformans* [5, 7-9]. The comparison among yeasts proved that *Saccharomyces cerevisiae* is more susceptible to TAM (MIC, 12 µg/ml) than *Candida albicans* (MIC, 32 µg/ml) and *Cryptococcus neoformans* (MIC, 64 µg/ml) [7]. It was shown that TAM had high activity against *C. neoformans*, either *in vitro* at MIC 8 µg/ml or inside macrophages [5, 8]. Meanwhile, treatment of the patient with cryptococcal infection may require a higher concentration of TAM. Randomized controlled trials have demonstrated that increasing the TAM dose from an *in vitro* effective concentration (8 µg/ml) to a high dose (300 mg/day) failed to eliminate *C. neoformans* from the cerebrospinal fluid of patients with cryptococcal meningitis [10]. Among *Candida* species, *C. albicans* is the most common species used to evaluate antifungal action of TAM [2, 9]. This yeast has been found to be more susceptible to TAM than other types of yeast such as *Cryptococcus laurentii* [9].

Isolates of *Candida* resistant to itraconazole were mainly selected to be specific fungi used in this study to evaluate their susceptibility to TAM. Itraconazole resistance is the second health problem that women face during treating candidiasis following the failure of fluconazole therapy [11]. This resistance to the most effective antifungals has encouraged the investigation of new alternative drugs. The antifungal effect of TAM on drug-resistant yeasts has been illustrated by few studies [12-13]. Some of these studies indirectly mention

How to cite this article: AL-Janabi Ali Abdul Hussein S. Potency of tamoxifen against clinical isolates of *Candida* resistant to itraconazole. J Res Pharm. 2023; 27(6): 2530-2534.

the inhibiting activity of TAM on a resistant fungal isolate [9, 14]. In addition, TAM showed the same activity pattern against susceptible and resistant isolates of *C. albicans* [12, 14]. Thus, the antifungal action of TAM on clinical isolates of *Candida* resistant to itraconazole was evaluated.

2. RESULTS

In the present study, fifteen isolates related to three species of *Candida* were found to be resistant to itraconazole. These isolates consisted of four isolates of *C. albicans*, ten isolates of *C. glabrata* and one isolate of *C. utilis*. Antifungal action of TAM was tested on these itraconazole-resistant isolates. The measurement of the zone of inhibition showed that all isolates were inhibited by the higher TAM concentration (20 mg/ml). Isolates of *C. albicans* were susceptible to TAM at a concentration of 10 mg/ml with a MIC ranging from 5.5 to 7 mg/ml. *C. glabrata* was the most susceptible species to TAM in which some of its isolates were inhibited at 5 mg/ml of TAM. It required variable MIC value of TAM for inhibition, ranging from a low (3 mg/ml, for *C. glabrata*-9) to a high MIC (8.5 mg/ml for *C. glabrata*-7). *C. utilis* was the most resistant isolate of *Candida* to TAM (MIC, 15 mg/ml)(Table 1).

Table 1. Zone of inhibition and minimum inhibitory concentration (MIC) of tamoxifen on *Candida* isolates

Fungal isolate	Zone of inhibition (mm)						Clotrimazole 10 µg/ml	MIC (mg/ml)
	Tamoxifen concentration (mg/ml)							
	20	10	5	2.5	1.25	0.625		
<i>C. albicans</i> -1	17	15	-	-	-	-	15	5.5
<i>C. albicans</i> -2	14	11	-	-	-	-	16	7
<i>C. albicans</i> -3	15	13	-	-	-	-	14	6.5
<i>C. albicans</i> -4	16	12	-	-	-	-	15	7
<i>C. glabrata</i> -1	18	14	10	-	-	-	17	3.5
<i>C. glabrata</i> -2	18	13	11	-	-	-	18	4
<i>C. glabrata</i> -3	13	10	-	-	-	-	16	8
<i>C. glabrata</i> -4	15	10	10	-	-	-	14	3.5
<i>C. glabrata</i> -5	12	12	-	-	-	-	15	7
<i>C. glabrata</i> -6	14	11	-	-	-	-	12	7.5
<i>C. glabrata</i> -7	11	9	-	-	-	-	12	8.5
<i>C. glabrata</i> -8	13	11	-	-	-	-	13	8
<i>C. glabrata</i> -9	15	12	9	-	-	-	15	3
<i>C. glabrata</i> -10	13	10	-	-	-	-	13	8
<i>C. utilis</i>	10	-	-	-	-	-	10	15

-: resistance

3. DISCUSSION

In the present study, *C. albicans* showed higher resistance to TAM, which was also demonstrated by another study [8]. The susceptibility of *Candida* spp. to TAM can be increased by converting TAM to metabolites such as 4-hydroxy-tamoxifen and endoxifen [5,8]. In general, pathogenic *C. albicans* without any azole resistance is usually susceptible to TAM [18]. This fungus usually requires 32 µg/ml of TAM for inhibition [7]. Evaluation of the effect of TAM on the logarithmic growth phase of *C. albicans* indicated that 2×10^{-5} M (7.43 mg/ml) of the TAM had a high fungicidal effect compared to 5×10^{-6} M (1.85 mg/ml) [19]. This is also clarified by the result of another study which showed that the stationary and logarithmic growth phases of *C. albicans* are inhibited by 15×10^{-6} M (5.57 mg/ml) to 20×10^{-6} M (7.43 mg/ml) of TAM [20]. The early and mature biofilm of *C. albicans* was also inhibited by a concentration of 1-4 mg/ml of TAM [21]. In a previous study, *C. albicans* isolated from the oral cavity of breast cancer patients showed greater susceptibility to TAM at concentrations of 5 and 10 µg/ml compared to other yeasts [9]. Such an inhibitory action of TAM has also been found in *C. albicans* isolated from a periodontitis lesion of women with breast cancer in which TAM also reduced the severity of periodontitis after 2 years of treatment with TAM [12]. An *in vivo* study in mice infected with *C. albicans* showed that mice treated with 200 mg/kg of TAM for 7 days reduced the burden of renal candidiasis [7].

Inhibition of itraconazole-resistant isolates of *Candida* in this study required high concentrations of TAM. Other resistant isolates of *C. albicans* are usually susceptible to low concentrations of TAM [12, 14]. Fluconazole-resistant isolate of *C. albicans* from the mouth of breast cancer patients was inhibited by 22.33 µM (8.29 mg/ml) of TAM with 31 times more than by fluconazole [12]. One other fluconazole-resistant isolate of *C. albicans* is inhibited by 200 µg/ml of TAM [14]. In addition, TAM was also able to increase the sensitivity of azole-resistant *C. albicans* to fluconazole [13].

Resistant isolates of *C. glabrata* to itraconazole in the current study showed a greater susceptibility to TAM. The normal isolate of *C. glabrata* may, in some cases, require a lower concentration of TAM for inhibition than *C. albicans* [7]. The clotrimazole-resistant isolate of *C. glabrata* was found to be highly inhibited at concentrations of 5 and 10 µg/ml of TAM [9]. Long-term TAM treatment for patients with vulvovaginal candidiasis caused by *C. glabrata* leads to an increased rate of recurrent infection with this fungus [22]. However, *C. glabrata* is usually more resistant to antifungals than *C. albicans* [23]. Thus, the susceptibility of *C. glabrata* to TAM in the present study can make TAM a promising treatment for infections caused by this resistant species.

The antifungal activity of TAM depends principally on the targeting of fungal calmodulin in the same way as for mammalian cells [7]. The presence of TAM prevents the binding of the EF hand motifs of the protein calmodulin with its calcineurin substrate which ultimately inhibits the calmodulin-calcineurin pathway [2, 4-8, 18]. Blockage of this pathway can affect many fungal cell activities, such as increased cell lysis, disturbed polarization of the membrane actin, and decreased formation of reproductive bud and germ tube [7]. The treatment of *C. albicans* with 16 µg/ml of TAM showed a reduction in filament formation and a modification in cell wall architecture by decreasing the amounts of mannoproteins covering 1,3-β-glucan [18]. In addition, the antifungal effect of TAM is affected by the pH in which its fungicide action against *C. albicans* decreases with acidity and increases with pH from 7 to 7.5 in a concentration-dependent manner [24].

TAM has a number of features that make it appropriate for use as an antimicrobial or antifungal agent. The most important pharmaceutical characteristics of TAM are its low adverse effects, its oral availability and its easy distribution to many tissues for rapid arrival at the site of infection [4]. Other features of TAM that make it a good antimicrobial agent are its activation of macrophage immune activity by interacting with the macrophage lipid mediators or signaling pathway and its easy penetration of macrophages to reach an internal pathogen [4-5]. TAM is also able to exert a synergistic effect on many antifungal agents against various fungal pathogens [2, 13]. The combination of different azoles with TAM increases their antifungal action against *C. neoformans* more than when they are used alone because TAM inhibits protein synthesis and azole inhibit ergosterol synthesis [6]. The antifungal activity of fluconazole against *C. neoformans* is also increased by combination with TAM at *in vitro* and *in vivo* levels [5]. However, combining may not always be effective or useful for many antifungals in some cases of fungal infections. No synergic effects were observed between fluconazole or amphotericin B and TAM against *C. neoformans* [10]. Fungicidal and fungistatic effects of miconazole against *C. albicans* are also unaffected by the combination with TAM [25].

4. CONCLUSION

Tamoxifen has variable effects on drug-resistant pathogenic species of *Candida*. Its antifungal action on *C. albicans* and *C. utilis* is not sufficiently strong to recommend its usage during the treatment their infections. TAM may be useful for treating infections caused by itraconazole-resistant isolates of *C. glabrata*. Considering TAM as a new antifungal agent for the treatment of an untreatable fungal infection is primarily dependent on increasing its concentration.

5. MATERIALS AND METHODS

5.1 Fungal isolation

In total, 50 *Candida* isolates were collected by vaginal swab from women volunteers with clinical confirmation of vulvovaginal candidiasis (23-57 years) from June to July 2021. The swabs were immediately microscopically examined and cultured on a Mueller-Hinton agar (MHA)(HiMedia, India) then incubated at 35° C for 24-48 hours. The morphological features of the isolates were identified as primary diagnosis by staining with crystal violet of Gram stain. Confirmation diagnosis was made using VITEK2 compact system with VITEK® 2 YST ID cards for yeast (BioMérieux, France).

5.2. Antimicrobial susceptibility test

Susceptibility of isolates was determined using a disk diffusion method referred by the CLSI-M44 (2018) [15]. A suspension of fungal growth was prepared by cultivating about 5 colonies of isolate from refresh subculture in 2 ml of sterilized Mueller-Hinton broth (MHB)(Himedia, India) and adjusted to the standard 0.5 McFarland to reach 1.5×10⁸ cfu/ml. A swab from inoculate was stripped over the MHA. A two-fold serial dilution was used to prepare different concentrations of TAM, ranging from 0.625 mg/ml to 20 mg/ml by dissolving it in ethanol. A number of 6 mm diameter disks were made from filter paper and sterilized. The disks with different concentrations of TAM were prepared at the time and loaded onto inoculated plates. Plates were incubated at 35° C for 24 hours. Disks with sterilized distilled water (D.W.) or ethanol were used as negative controls. Clotrimazole (10 µg/ml), a standard antifungal agent, was used as a positive control.

Diameter of the zone of inhibition was measured in mm around the effective disk. Resistance to itraconazole was confirmed when the zone of inhibition around the itraconazole disk (10 µg) (Torrejón de Ardoz, Madrid, Spain) was less than 24-25 mm [16].

5.3. Determination of minimum inhibition concentration (MIC)

The MIC value of the TAM was determined using the dilution method referenced by CLSI-M60 (2017) [17]. Isolated yeasts were subcultured in the MHB and incubated at 35°C for 24 hours. A plastic microdilution plate (96 wells) was used to determine the MIC value. Each well of plate was equipped with 100 µl of free of MHB, 50 µl of adjusted fungal counts, and 50 µl of each TAM concentration. Controls used in the disk diffusion method were also used in a microdilution plate. Inoculated plates were incubated at 35°C for 24 hours. Results were recorded depending on the presence or absence of growing was visually observed.

Acknowledgements: The author want to introduce a great thankfulness to Mr. Philip Smith for his assistance in language corrections.

Author contributions: Concept - A.A.; Design - A.A.; Supervision - A.A.; Resources - A.A.; Materials - A.A.; Data Collection and/or Processing - A.A.; Analysis and/or Interpretation - A.A.; Literature Search - A.A.; Writing - A.A.; Critical Reviews - A.A.

Conflict of interest statement: The authors declared no conflict of interest in the manuscript.

REFERENCES

- [1] Bouz G, Doležal M. 2021. Advances in antifungal drug development: an up-to-date mini review. *Pharmaceuticals*. 14, 1312. <https://org/10.3390/ph14121312>.
- [2] AL-Janabi AAH, AI-Mosawe HA. 2019. Tamoxifen: from anti-cancer to antifungal drug. *Int J Med Rev*. 6:88-91. <https://org/10.29252/IJMR-060304>.
- [3] Wiseman H, Quinn P, Halliwell B. 1993. Tamoxifen and related compounds decrease membrane fluidity in liposomes: mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions?. *FEBS Lett*. 330: 53-56. [https://org/10.1016/0014-5793\(93\)80918-k](https://org/10.1016/0014-5793(93)80918-k).
- [4] Sfogliarini C, Pepe G, Dolce A, Torre SD, Cesta MC, Allegretti M, Locati M, Vegeto E. 2022. Tamoxifen twists again: on and off-targets in macrophages and infections. *Front Pharmacol*. 13:879020. <https://org/10.3389/fphar.2022.879020>.
- [5] Butts A, Koselny K, Chabrier-Rosell Y, Semighini CP, Brown JC, Wang X, Annadurai S, DiDone L, Tabroff J, Childers WE, Abou-Gharbia M, Wellington M, Cardenas ME, Madhani HD, Heitman J, Krysan DJ. 2014. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole *in vitro*. *mBio*. 5:1-11. <https://org/10.1128/mBio.00765-13>.
- [6] Zhang X, Fang Y, Jaiseng W, Hu L, Lu Y, Ma Y, Furuyashiki T. 2015. Characterization of tamoxifen as an antifungal agent using the yeast *Schizosaccharomyces pombe* model organism. *Kobe J Med Sci*. 61:E54-E63.
- [7] Dolan K, Montgomery S, Buchheit B, DiDone L, Wellington M, Krysan DJ. 2009. Antifungal activity of tamoxifen: *In vitro* and *in vivo* activities and mechanistic characterization. *Antimicrob Agents Chemother*. 53: 3337-3346. <https://org/10.1128/AAC01564-08>.
- [8] Butts A, Martin JA, DiDone L, Bradley EK, Mutz M, Krysan DJ. 2015. Structure-activity relationships for the antifungal activity of selected estrogen receptor antagonists related to tamoxifen. *PLoS ONE*, 10: e0125927. <https://org/10.1371/journal.pone.0125927>.
- [9] AL-Janabi AA, AI-Mosawe HA. 2021. Effects of tamoxifen as an antifungal agent against oral cavity yeasts *in-vitro* and in breast cancer patients. *J Kermanshah Univ Med Sci*. 25(2): e102989. <https://org/10.5812/jkums.102989>.
- [10] Ngan NTT, Le NTH, Vi NNV, Van NTT, Mai NTH, Anh DV, Trieu PH, et al. 2021. An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. *Elife*. 10:e68929. <https://org/10.7554/elife.68929>.
- [11] Martin MV. 1999. The use of fluconazole and itraconazole in the treatment of *Candida albicans* infections: a review. *J Antimicrob Chemother*. 44:429-237. <https://org/10.1093/jac/44.4.429>.
- [12] Muthular M, Bálsamo F, Passero P, Jewtuchowicz V, Miozza V, Villalba MB, Brusca MI, Pérez C. 2019. Effects of tamoxifen on periodontal disease and *Candida albicans* of patients with breast cancer and other pathologies. *Future Microbiol*. 14:129-137. <https://org/10.2217/fmb-2018-0272>.

- [13] Eldesouky HE, Salama EA, Hazbun TR, Mayhoub AS, Seleem MN. 2020. Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities. *Sci Rep.* 10:6089. <https://org/10.1038/s41598-020-62976-y>.
- [14] Routh MM, Raut JS, Karuppayil SM. 2011. Dual properties of anticancer agents: an exploratory study on the *in vitro* anti-Candida properties of thirty drugs. *Chemotherapy.* 57:372-380. <https://org/10.1159/000330454>.
- [15] Clinical and Laboratory Standards Institute (CLSI). 2018. Method for antifungal disk diffusion susceptibility testing of yeasts: Approved standard-3rd edition. Document M44. Wayne, Pennsylvania. 38(24).
- [16] Espinel-Ingroff A, Canton E, Gibbs D, Wang A. 2007. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of *Candida* spp. and *Cryptococcus neoformans* to amphotericin B, caspofungin, fluconazole, itraconazole and voriconazole. *J Clin Microbiol.* 45:858-864.. <https://org/10.1128/JCM.01900-06>.
- [17] Clinical and Laboratory Standards Institute (CLSI). 2020. Performance standards for antifungal susceptibility testing of yeasts: Approved standard-2nd edition. Document M60. Wayne, Pennsylvania. 40(8).
- [18] Tabroff JM, DiDone LP, Koselny K. 2010. Antifungal activity of tamoxifen and its analogs against the opportunistic pathogen, *Candida albicans*. *JUR.* 9:22-28.
- [19] Beggs WH. 1993. Anti-Candida activity of the anti-cancer drug tamoxifen. *Res Commun Chem Pathol Pharmacol.* 80:125-128.
- [20] Beggs WH. 1995. Growth phase in relation to the lethal action of tamoxifen on *Candida albicans*. *Res Commun Mol Pathol Pharmacol.* 88:115-118.
- [21] Wakharde AA, Halbandge SD, Phule DB, Karuppayil SM. 2018. Anticancer drugs as antibiofilm agents in *Candida albicans*: potential targets. *Assay Drug Dev Technol.* 16:232-246. <https://org/10.1089/adt.2017.826>.
- [22] Sobel JD, Chaim W, Leaman D. 1996. Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women. *Obstet Gynecol.* 88:704-706. [https://org/10.1016/0029-7844\(96\)00123-8](https://org/10.1016/0029-7844(96)00123-8).
- [23] Dabas PS. 2013. An approach to etiology, diagnosis and management of different types of candidiasis. *J Yeast Fungal Res.* 4:63-74. <https://org/10.5897/JYFR2013.0113>.
- [24] Beggs WH. 1996. Drug protonation and pH in relation to the lethal action of tamoxifen on *Candida albicans*. *J Antimicrob Chemother.* 37:841-842. . <https://org/10.1093/jac/37.4.841>.
- [25] Beggs WH. 1994. Comparative activities of miconazole and the anticancer drug tamoxifen against *Candida albicans*. *J Antimicrob Chemotherapy.* 34:186-187. <https://org/10.1093/jac/34.1.186>.